Intnl. Biotechnology - Half Yearly Report
03/05/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230503:nRSC1849Ya&default-theme=true
RNS Number : 1849Y Intl. Biotechnology Trust PLC 03 May 2023
3 May 2023
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
("IBT" or the "Company")
Half Yearly Report for the six months ended 28 February 2023
CHAIR'S STATEMENT
I am pleased to report that the Fund Manager has again produced a strong set
of results in the first six months ended 28 February 2023. This is my first
report since taking over as Chair in December, and I would like to record my
thanks to Jim Horsburgh for his tenure. The Company's share price returned
8.0% over the six month period, well ahead of the Nasdaq Biotechnology Index
(NBI), which had a total return of 1.8%. The Company's Net Asset Value (NAV)
total return over the period was 6.1%. Over three years to the end of February
2023, the total share price return was 43.2%, versus 22.6% for the NBI, and
the Company's share price was also ahead over five years with a total return
of 43.8% versus 41.2% for the NBI. All figures are on a sterling adjusted
total return basis, with dividends reinvested.
These returns are all the more impressive given the continued upheaval in
global equity markets. Markets worldwide are grappling with high levels of
inflation and rising interest rates, the ongoing conflict in Ukraine and
increasing geopolitical tension between the US and China. The abandonment of
the Zero COVID-19 policy in China led to a recovery in global, and
particularly, Asian markets during the period, whilst political gyrations in
the UK in September led to a fall in the FTSE, followed by a recovery in the
final months of 2022. The frothy valuations seen in the biotechnology sector
during the pandemic have now been largely unwound, which has led to a more
fertile environment for M&A activity. Both the quoted portfolio and the
unquoted portfolio benefitted from being invested in takeover targets during
the first six months of the Company's financial year.
QUOTED PORTFOLIO
Our joint lead Investment Managers, Ailsa Craig and Marek Poszepczynski have
continued to focus on identifying revenue generating innovative biotech
opportunities with significant success. During the six months ended 28
February 2023, the NAV per share of the quoted portfolio returned 5.8%,
substantially outperforming the reference benchmark of the NBI which returned
1.8%.
During the period under review, the portfolio benefitted from having positions
in three quoted companies which were the subject of takeover bids. Of
particular note, was the announcement in December 2022 of the acquisition of
Horizon Therapeutics by Amgen, which has not yet completed and is subject to
regulatory approval. Amgen agreed to pay a premium of 47.9% above the last
closing price of Horizon Therapeutics prior to the announcement that the
company was the subject of a takeover bid on 29 November 2022. At the time of
the announcement Horizon was the largest position in the quoted portfolio
representing 13.5% of IBT's NAV.
The rising interest rate environment continues to have an impact on the
financing and valuation of smaller early stage biotech companies. The
Investment Managers' decision to overweight exposure towards larger biotech
companies with proven therapeutics which are already generating revenues has,
thus far, been vindicated.
UNQUOTED PORTFOLIO
The Investment Managers of the unquoted portfolio, Kate Bingham and Houman
Ashrafian have also achieved strong performance for investors over the period.
As at 28 February 2023, the unquoted portfolio comprised 11.8% of the
Company's NAV. The portfolio currently includes two unquoted funds, SV Fund VI
and SV BCOF as well as a small number of directly held unquoted companies,
most of which have been exited with contingent milestones.
SV Fund VI
SV Fund VI, which represents 5.8% of IBT's NAV, has performed well, delivering
a currency adjusted internal rate of return (IRR) of 20.5% per annum since the
Company's first investment in the fund in 2016. The Fund, which includes a
range of early-stage biotech, medical device and healthcare services
companies, is now a mature portfolio with 83% of the capital committed drawn
down. During the six months ended 28 February 2023, SV Fund VI made one
distribution of $1.8m (£1.6m) and one capital call of $0.9m (£0.8m).
SV BCOF
During the period under review, IBT increased its commitment to SV BCOF, the
newer fund which invests in later stage and/ or pre-IPO opportunities. SV BCOF
now represents 4.2% of IBT's NAV. The $30m commitment is only 27% drawn down,
but the fund has had a notable early success with a £5.5m uplift in the
period. In February 2023 Nimbus Therapeutics, an early BCOF investment, sold
its TYK2 Inhibitor, which had demonstrated promising Phase 2 results in
psoriasis, to Takeda for $4bn in upfront cash, and up to $2bn in commercial
milestone payments.
PERFORMANCE FEE
Thanks to outperformance in both the quoted and unquoted portfolios, a
performance fee of £199,000 has been accrued in the accounts for the six
months to 28 February 2023. The quoted portfolio achieved more than 10%
relative performance above the NBI benchmark plus a 0.5% hurdle rate which has
led to an accrual of £150,000 in performance fees. The accrued performance
fee of £49,000 on the unquoted portfolio is due to net realised gains during
the period.
DIVIDENDS
The Company's approved dividend policy (last approved at the 2022 AGM) is to
make dividend payments equivalent to 4% of the Company's NAV, as at the last
day of the preceding financial year ending 31 August through two equal
semi-annual distributions. The first dividend for the year of 14 pence per
share was paid on 27 January 2023. The Board intends to make the declaration
of the second dividend for the year in accordance with the above policy in
July for payment in August 2023.
DISCOUNT AND PREMIUM MANAGEMENT
The Board keeps the Company's share price discount to NAV under close review
and is committed to buying back its shares to help manage the discount.
Similarly, the Board is keen to grow the Company and will issue shares when
the share price is trading at a premium to NAV. During the six months under
review, 98,180 shares were bought back to be held in Treasury. The share price
discount to NAV, which was 6.6% at 31 August 2022 had narrowed to 4.8% at 28
February 2023.
ESG
The Board recognises the importance that investors place on their funds being
invested in responsible companies which generate sustainable returns. The
companies in which IBT invests have an important social impact through
extending and enhancing human life. Our Investment Managers seek to identify
companies which are developing innovative treatments for diseases where there
is a high unmet need, and where progress is not only profitable, but life
changing for patients.
In accordance with our ESG policy, the Investment Managers incorporate an ESG
screening process in the investment process. Data provided by Morningstar's
Sustainalytics is used to measure the environmental and social impact and the
quality of their governance in key portfolio holdings. The results of this
screen are outlined on page 15 of this report.
BOARD SUCCESSION
Following Jim Horsburgh's retirement from the Board, we engaged an independent
search consultant to help us identify a new director. I am delighted to
welcome Gillian Elcock, who joined the Board at the beginning of February
2023. Gillian was the founder and Managing Director of Denny Ellison, an
independent investment research company, and is a highly experienced equity
research analyst. Gillian is also a member of the Board of the CFA UK. Gillian
will stand for election at the Company's AGM in December.
CHANGE OF MANAGER
As announced on 13 February 2023, the Company's AIFM and Manager, SV Health
has decided to focus on its venture capital business and has served notice of
termination to IBT plc. Whilst this was an unexpected development, the Board
understands SV's decision and is pleased that the Investment Managers will
continue to focus on delivering results for shareholders during the transition
period.
In order to ensure that shareholders views are uppermost in our minds as we
deliberate on the future for IBT, the Board engaged with many of our key
shareholders following the announcement. We have listened to our shareholders
and sought to understand their perceptions of IBT's strengths and the key
reasons why they have chosen to invest. We have used this comprehensive
feedback to inform our decisions during the independent process of selecting a
new manager for IBT. I am pleased to report that we received many expressions
of interest in managing the Company's assets. Together with our professional
advisers, we narrowed this field down to a short list of candidates before
sending them request for proposals. We then selected six institutions to
present to the Board. At the time of writing, we are in the process of
reviewing the presentations we have received. Unfortunately, we are currently
unable to disclose further details during these confidential negotiations. We
are determined to minimise the period of uncertainty and expect to be able to
release more information in the near future. We would like to thank
shareholders for their support and patience.
OUTLOOK
Since the half year end in February, the risk of contagion following the
demise of Silicon Valley Bank and Signature Bank in the US, and Credit Suisse
in Europe, has sent shivers through the market. Nevertheless, the Board
believes that the biotechnology sector offers a very compelling long term
investment opportunity. Over the 20 years from the end of 2002 to the end of
2022 the NBI has produced an average return of 13.3% per annum versus 11.4%
for the S&P 500.
The aging global population will continue to ensure strong demand for
therapeutics to treat disease and enhance quality of life. We are living
through a period of great innovation in medical science, including exciting
advances in cell based and gene therapies, which have the potential to change
outcomes for patients suffering from diseases such as cancer and dementia. The
renewed focus on drug development following the global pandemic has
highlighted the potential for faster, more personalised clinical trials which
should reduce the risks of late stage failure.
Cash rich, large pharmaceutical companies needing to replenish their pipelines
are increasingly looking to the smaller revenue generating innovative
companies in which IBT invests. We share our Investment Managers' enthusiasm
that the current more realistic valuations and the prospects for increased
corporate activity in the biotech sector represent an excellent opportunity
for IBT shareholders.
KATE CORNISH-BOWDEN | Chair
2 May 2023
FUND MANAGER'S REVIEW
SUMMARY
In the six months to 28 February 2023, the NAV per share returned 6.1% and the
share price returned 8.0%. The Company's benchmark, the NASDAQ Biotechnology
Index, returned 1.8%. All figures are on a sterling adjusted total return
basis, with dividends reinvested.
By subsector, 74% of the portfolio was invested in therapeutics, 13% in
specialty pharmaceuticals and 4% in life sciences, tools, and diagnostics. 9%
of the Company was invested in venture funds.
The Company's three largest therapeutic areas were oncology 36%, rare diseases
16%, and diseases of the central nervous system 15%.
At the end of the period the Company's gearing position was 8.2% and the
Company's discount had narrowed from 6.6% to 4.8%.
QUOTED PORTFOLIO
For the six-month period ended 28 February 2023, the NAV of the quoted
portfolio returned 5.8%, versus 1.8% for the NASDAQ Biotechnology Index (gross
of management and performance fees). All figures are on a sterling adjusted
total return basis, with dividends reinvested.
Market Backdrop
During the period under review, global macro-economic conditions have
continued to be uncertain. Interest rates across the world have risen and
investors have been cautious about investing into areas deemed to be risky.
Continued inflationary pressure has caused monetary policy makers to increase
interest rates faster than anticipated. The rise in interest rates led to
renewed popularity of debt instruments. Following record inflows into equities
during the pandemic, the third quarter of 2022 saw record outflows from UK
equities following the brief tenure of Liz Truss as Prime Minister.
The biotech sector has seen a divergence in performance depending on the
characteristics of the specific biotech company. Smaller early stage companies
have struggled to keep their valuations compared to their larger, more
diversified peers. While innovation in these smaller companies has been
exciting, investors have held off from backing them due to concerns over
financing costs. In the last quarter of 2022 investors, fearing that the
rising valuations seen in technology companies were unsustainable, rotated
their focus into the largest biotech companies. In turn, those mega cap
biotech names which are usually considered to be slow growth in nature,
experienced an unexpected boost to performance. At the start of 2023,
following a correction in the global mega- cap technology companies, that
money retreated back into technology, causing a retraction in the 'safe haven'
mega cap biotech names. Meanwhile the performance of the mid- tier biotech
companies which have products that have been approved and are on the market
but have not yet turned profitable, have been relatively robust and several of
them have benefitted from the acquisition appetite of the cash-rich, large
biopharma companies.
The Nasdaq Biotech Index (NBI) outperformed the S&P 500 over the period by
4.5% while the equal weighted S&P Biotech ETF (XBI) underperformed by 6.7%
reflecting the relatively poor performance of smaller cap biotech companies
against the sector as a whole.
Mergers and acquisitions (M&A)
After a delay in M&A discussions driven partly by lockdowns in 2020 and
overheated valuations in 2021, 2022 saw a return to a normalised deal flow.
M&A is a hallmark of the healthcare ecosystem and in the period under
review the company benefitted from three acquisitions of its quoted portfolio
companies and a further one of its unquoted portfolio companies.
In December 2022, Amgen announced its intention to acquire portfolio company
Horizon, a revenue growth stage company with a treatment for Thyroid Eye
Disease. The deal was worth $28bn which represented a premium of 48% to the
share price.
At the time of the announcement the Company had a position of 13.5% of NAV.
This deal is not yet completed and is subject to regulatory approval.
In January 2023, Ipsen announced that it would acquire portfolio holding
Albireo, a revenue growth stage company with an approved treatment for a rare
liver disease. The deal was worth $952m which represented a premium of 104% to
the share price. At the time of the announcement the Company had a position of
0.23% of NAV.
Also in January 2023, Sun Pharma announced its intention to acquire Concert
Pharmaceuticals. Concert Pharmaceuticals is a development stage company with
an oral treatment for alopecia areata in late stage clinical trials. The deal
was worth $580m which represented a premium of 33% to the share price. At the
time of the announcement the Company had a position of 0.33% of NAV.
Following the end of the period under review, on 13 March 2023, Pfizer
announced that it had entered an agreement to acquire portfolio holding Seagen
for $43bn which represented a premium of 32.7% to the share price. At the time
of the announcement, the Company had a position of 10.2% of NAV.
Positive contributors to the NAV
BEST PERFORMING INVESTMENTS
Contributors to NAV (£'m)
Horizon Therapeutics 16.8
Gilead Sciences 3.0
Biogen Inc 3.0
Amgen announced its intention to acquire Horizon Therapeutics for $28bn in
December 2022. The company is focused on rare diseases, where Tepezza for
thyroid eye disease (TED), the only approved drug to treat the disease, is the
largest product. TED is a condition which results in a build up of fat tissue
behind the eyes. The symptoms can cause double vision and bulging eyes.
Despite the logistical complications arising from the COVID-19 pandemic at the
time, the Tepezza launch was the most successful rare disease product launch
of all time.
In the period under review, Gilead shares benefitted from the company's HIV
and cell therapy franchises that reported stronger sales than expected. Also
in the wake of general market turbulence in 2022, larger biopharma companies
including Gilead performed well as a group in the autumn when money flowed out
of large cap technology stocks into the perceived 'safer haven' biopharma
companies. Biogen, and partner Japanese pharmaceutical company Eisai, reported
positive results for their Alzheimer's disease candidate lecanemab. The
CLARITY-AD phase 3 trial hit its primary and key secondary endpoints. This
large clinical trial compared lecanemab, an antibody that targets and
eliminates amyloid-beta plaques, against placebo. The drug was found to reduce
cognitive decline by 27% compared to placebo. Following on from this,
lecanemab received approval from the Food & Drug Administration in January
2023 and was subsequently launched under the brand name 'leqembi'.
Negative detractors to NAV
WORST PERFORMING INVESTMENTS
Detractors from NAV (£'m)
Vera Therapeutics -3.7
KalVista Pharmaceuticals -3.1
Novavax Inc -2.8
Vera Therapeutics reported phase two data in early January 2023 for its drug
atacicept for immunoglobulin A nephropathy (IgAN), an autoimmune disease which
attacks the kidneys. Atacicept has a dual APRIL/BLyS inhibition aiming to
reduce the level of proteinuria in patients. Successfully reducing proteinuria
is considered to be linked to longer term improvement of kidney function. The
trial succeeded and showed a 30% reduction in proteinuria levels at nine
months; however, investors had hoped for a greater reduction causing a
sell-off in the shares.
KalVista announced it would be discontinuing a clinical trial investigating a
prophylactic treatment for Hereditary Angioedema, a disorder characterised by
recurrent episodes of severe swelling. KVD824 was in mid stage clinical trials
for the rare condition and unfortunately was stopped due to unanticipated
safety signals in some patients. The management therefore took the decision to
terminate the programme.
Novavax successfully developed a vaccine for COVID-19 called Nuvaxovid which
was approved for use in July of 2022. However, due to a litany of setbacks,
including manufacturing issues, and being third to market after Moderna and
Pfizer/ BioNTech, the company failed to generate material sales.
UNQUOTED PORTFOLIO
Summary of unquoted investments
As at 28 February 2023 As at 31 August 2022
Fair value % of NAV No. of Fair value % of NAV No. of investments
(£'m) investments (£'m)
Unquoted funds 29.3 10.0% 24* 22.4 7.8% 24*
Exited with contingent milestones 5.0 1.7% 5 5.3 1.8% 5
Directly-held unquoted 0.4 0.1% 2 0.3 0.1% 1
Total unquoted 34.7 11.8% 31 28.0 9.7% 30
* The number of investments within unquoted funds represents the number of
investments into underlying individual portfolio companies. Three of these
companies were quoted as at 28 February 2023.
The Company's unquoted portfolio continues to perform well in its objective to
give investors exposure to differentiated returns from quoted markets and
access to innovative early stage companies. As at 28 February 2023, it
comprised 11.8% of the Company's Net Asset Value (NAV) which is in line with
the Company's strategy of maintaining its exposure to unquoted companies
within 5-15% of total NAV.
The portfolio currently comprises investment in two unquoted funds, SV Fund VI
and SV BCOF as well as a small number of directly held unquoted companies,
most of which have exited with contingent milestones.
SV Fund VI is the Company's most significant unquoted investment and has
performed well delivering a currency adjusted internal rate of return (IRR) of
20.5% per annum since the date of the Company's first investment in the fund
in 2016. During the six months ended 28 February 2023, SV Fund VI made one
distribution of $1.8m (£1.6m) and one capital call of $0.9m (£0.8m). The
draw down to date on the commitment of $30.0m is $24.9m, which represents
83.1% of the total committed capital.
SV BCOF focuses on later stage and/or pre-IPO opportunities and invests in
clinical and near clinical stage biotech companies in the UK, EU and US that
have the potential to deliver excellent investor returns and address
significant unmet medical needs in patients.
During the period, the Company committed a further $5m (£4.2m), which raised
its total commitment to $30m. Since December 2021, $8.3m of this capital has
been invested. The fund has performed well due to one of its investments,
Nimbus Therapeutics, being the subject of an acquisition. In February 2023,
Takeda acquired Nimbus Lakshmi Inc, a wholly-owned subsidiary of Nimbus and
its TYK2 inhibitor (NDI-034858) for $4bn in upfront cash, and up to $2bn in
commercial milestone payments.
A fair value uplift of £5.5m was applied to the Company's investment in the
fund, primarily as a result of the above Nimbus transaction.
OUTLOOK
The fundamentals underpinning the biotech industry are ever more compelling.
On the demand side, the global population continues to be more heavily
weighted towards the over 60s which is driving demand for medicines. Further,
a growing middle class in developing markets is demanding better access to
healthcare which is increasing the global take up of new drugs. The biotech
industry is keeping up with this demand through an accelerating pace of
innovation and an evolving regulatory backdrop that is enabling drugs to reach
the market in a more efficient manner.
The 2023 to 2028 period will see an increase in the number of treatments
reaching their patent expiry dates. While the prevalence of less easy to
replicate biologics will mean that copycat therapies are generally slower to
take hold, there is pressure on the big pharmaceutical companies to plug the
impending revenue gaps in their product pipelines with new treatments.
The Investment Managers believe that big pharmaceutical companies, especially
those with sound balance sheets stemming from COVID-19 vaccine and treatments
sales, will be looking to deploy their cash and build their drug pipelines.
Rather than focussing on early-stage biotech, the Investment Managers expect
them to target de-risked companies with a shorter time horizon to
profitability such as the 'revenue growth' names that already were the subject
of acquisitions in the six months to February 2023.
With macro-economic uncertainty continuing and questions over access to
affordable, reliable financing, the Investment Managers expect to continue to
tilt the portfolio in favour of revenue growth and large cap biotech companies
with carefully selected, well financed smaller cap names addressing the
highest unmet needs making up the remainder of the portfolio.
Catalysts for 2023 are likely to include positive clinical readouts, good
product launches, a steady flow of M&A deals and a reignition of biotech
sector IPOs. Together, these could underpin investor interest in the sector
and boost returns into the future. The Company is well positioned to benefit
from these situations as they occur.
SV HEALTH MANAGERS LLP
2 May 2023
ENVIRONMENTAL, SOCIAL AND GOVERNANCE POLICY
The Company outlined its Environmental, Social and Governance (ESG) policy in
its Annual Report for the year ended August 2021.
Its policy was adopted in October 2021, and since amended in February 2023, in
conjunction with IBT's Fund Manager, SV Health Investors, and aims to
integrate consideration for ESG factors into the investment process,
governance and choice of suppliers for IBT and to exert influence on portfolio
companies and suppliers to consider ESG factors in their respective
activities. IBT's Board also considers ESG factors in its choice of suppliers.
All of IBT's investments and activities are aligned with UN Sustainable
Development Goal number 3: 'Good Health and Well-being. Ensure healthy lives
and promote well-being for all at all ages.' as well as six other goals. IBT
is dedicated to investing in tomorrow's healthcare breakthroughs. IBT has
invested in scientific development, medical innovation, and technologies
across a wide spectrum of diseases with particular focus on areas of high
unmet medical need. IBT also adheres to all six UN Principles for Responsible
Investment and supports all the Ten Principles of the UN Global Compact.
ESG REPORT
The Company has been delivering financial value to shareholders since 1994
whilst simultaneously creating a positive social impact by investing in
companies that develop innovative treatments for patients suffering with unmet
medical needs. The products developed by the companies we invest in can
radically change the way diseases are treated, bringing positive impact to
patients and healthcare systems globally.
IBT's investment approach in relation to ESG is based on three pillars:
1. Thorough ESG diligence and investing for impact;
2. Meaningful engagement with portfolio companies; and
3. Reporting to shareholders.
The Board considers that focussing on the ESG compliance of its investments
and engaging with the management of key portfolio companies has the potential
to bring about positive change in its investment universe. In particular, IBT
believes its potential to generate the greatest impact will generally be on
its top ten quoted holdings and its private holdings where IBT's larger
investment size gives it greater influence.
The Board notes that ESG and sustainability concerns have become key
considerations for many of its investors. The Board believes that through
IBT's focus on ESG as an investor, it can help maximise its portfolio
companies' positive impact whilst generating attractive investor returns.
In its Annual Report for the year ended 31 August 2022, IBT outlined the
difficulties it had experienced in gathering meaningful data relating to the
ESG compliance or otherwise of its top ten quoted holdings. As a result of
that, a new policy has been designed which has been published on IBT's website
at https://ibtplc.com/esg-policy (https://ibtplc.com/esg-policy) .
The key difference in the policy is that IBT has now subscribed to the
services of an external ESG monitoring agency, Sustainalytics which is part of
Morningstar's platform, rather than using its bespoke ESG survey for its
quoted portfolio. The decision to make this change was made after experiencing
resistance from quoted portfolio companies to completing a bespoke ESG survey
from a minority shareholder like IBT. This reflected the increasing pressure
on companies from investors to give ESG information which in turn should lead
to greater ESG awareness at portfolio companies. As a result of this pressure,
companies are moving away from individual responses and are instead directing
investors to their public ESG policies which makes meaningful comparisons of
companies difficult.
Going forward, IBT intends to use the data gathered by Sustainalytics to
monitor the compliance of its quoted portfolio with an accepted set of ESG
standards. The benefit of this service means that IBT has access to a detailed
set of ESG data on the majority of the quoted biotech universe which not only
facilitates ESG reporting and enables comparisons to benchmarks beyond IBT's
own portfolio, but also enables the incorporation of ESG screening into its
portfolio management process. In addition, the access to this data means that
IBT's Fund Managers can more readily engage with portfolio companies in
respect to areas in which Sustainalytics considers them to fall short of their
peers. IBT continues to commit to screening and reporting on the ESG
compliance of its top ten quoted portfolio companies in aggregate on a
semi-annual basis to coincide with the annual and interim period ends.
IBT's screening of the biotech companies in its unquoted portfolio will take
place annually as before and will continue to depend on those companies
completing SV's bespoke ESG screening questionnaire. This was reported on in
the Annual Report for the year ended 31 August 2022. Of note, however, is that
in October 2022, we are pleased to report that Sustainalytics ranked one of
the companies held in SV BCOF as having the lowest ESG Risk rating in the
industry.
IBT continues to request its suppliers to provide ESG policies annually and
seven of its suppliers have agreed to have links to their policies displayed
on IBT's website.
Sustainalytics ranks the pharmaceutical and biotech industries in aggregate as
relatively high risk in comparison to other industries. This is mainly driven
by a combination of poor Quality and Safety scores (relating to drugs in
clinical trials being found to be inefficacious or toxic), Business Ethics
issues relating to drug pricing and availability and "Weak" management scores,
relating, in the main, to poor disclosure or perceived failure to adequately
mitigate the risks inherent in the industry. Arguably the Quality and Safety
issues and Business Ethics issues are part and parcel of drug development and
difficult for companies to avoid. Against that backdrop, it is unsurprising
that Sustainalytics rates over 55% of companies as having Severe (14%) or High
(42%) ESG Risk, with only 8% having Low ESG Risk.
In respect of the six months ended February 2023, we are pleased to report
that 70% of IBT's top ten quoted holdings were rated with a Medium ESG Risk
Score compared with 36% of the industry as a whole. Three of the top ten
quoted companies were categorised as High ESG Risk with the highest risk of
these falling in the 67th percentile of biotech companies screened by
Sustainalytics and the others between the 20th and 40th percentile. None of
IBT's top ten quoted companies were rated in the Severe category of ESG Risk.
On a positive note, all three of the High ESG Risk companies in the top ten
quoted companies are shown to be on a positive trajectory in comparison to
their previous Sustainalytics screening. One of the three companies
categorised as High ESG Risk has been the subject of recent active engagement
by IBT's Investment Managers and we are pleased to see an improvement in its
ranking. IBT's Investment Managers have closely examined the background behind
the current ESG rankings of those companies categorised as High ESG Risk and
established that the majority of the issues that have contributed to their
High ESG Risk rating results from lack of disclosure rather than from any
specific avoidable activity deemed to be counter to ESG principles. IBT's
Investment Managers will engage with these companies over the coming months to
ensure that the current disclosure is not concealing anything of concern, and
to encourage them to adhere to best practice on disclosure.
IBT's Investment Managers look forward to having better access to ESG data on
their portfolio through this new relationship with Sustainalytics and using it
as the basis for meaningful engagement on ESG matters with portfolio companies
going forward as well as highlighting any areas of concern. IBT continues to
negatively screen companies which would exclude from potential investment any
companies which engage in certain unsavoury practices, such as price gouging,
involvement in the US opioid scandal, "me-too" drugs lacking innovation and
anything that leads to negative effects on public health or wellbeing.
INTERIM MANAGEMENT REPORT AND DIRECTORS' RESPONSIBILITIES STATEMENT
Interim Management Report
The important events that have occurred during the period under review, the
key factors influencing the financial statements and the principal risks and
uncertainties for the remaining six months of the financial year are set out
in the Chair's Statement on pages 7 to 9 and the Fund Manager's Review on
pages 10 to 13.
The principal and emerging risks facing the Company are substantially
unchanged since the date of the Annual Report and Accounts for the year ended
31 August 2022 and continue to be as set out in that report on pages 25 to 26.
As detailed in the Chair's Statement on page 9, the Manager, SV Health has
served notice of termination to IBT. The Board is working closely with its
advisers to manage the risks associated with selection of, and transition to,
a new Manager.
Risks faced by the Company include, but are not limited to,
strategic/performance risk, political risk, investment related risks,
operational and service provider risks and tax, legal and regulatory risks.
Directors' Responsibilities Statement
In respect of the Interim Report for the six months ended 28 February 2023, we
confirm that, to the best of our knowledge:
• the condensed set of Financial Statements contained within have been
prepared in accordance with IAS 34 Interim Financial Reporting and give a true
and fair view of the assets, liabilities, financial position and profit and
loss of the Company as at 28 February 2023 as required by the Disclosure
Guidance and Transparency Rule 4.2.4R;
• the Interim Report includes a fair review as required by Disclosure
Guidance and Transparency Rule 4.2.7R, of important events that have occurred
during the six months to 28 February 2023 and their impact on the condensed
set of Financial Statements, and a description of the principal and emerging
risks for the remaining six months of the financial year; and
• the Interim Report includes a fair review of the information concerning
related party transactions as required by Disclosure Guidance and Transparency
Rule 4.2.8R.
The Interim Report has not been reviewed or audited by the Company's Auditors.
The Interim Report for the six months ended 28 February 2023 was approved by
the Board and the above Responsibilities Statement has been signed on its
behalf by:
KATE CORNISH-BOWDEN | Chair
2 May 2023
STATEMENT OF COMPREHENSIVE INCOME
(Unaudited) (Unaudited) (Audited)
For the six months ended For the six months ended For the year ended
28 February 2023
28 February 2022
31 August 2022
Revenue Capital Total Revenue Capital Total Revenue Capital Total
Notes £'000 £'000 £'000 £'000 £'000 £'000 £'000 £'000 £'000
Gains/(losses) on investments held at fair value - 18,294 18,294 - (46,452) (46,452) - (14,696) (14,696)
Exchange gains/(losses) on currency balances - 564 564 - (609) (609) - (4,378) (4,378)
Income 2 447 - 447 647 - 647 1,113 - 1,113
Expenses - - -
Management fee (873) - (873) (1,289) - (1,289) (2,009) - (2,009)
Performance fee - (199) (199) - - - - (471) (471)
Administrative expenses (659) - (659) (575) - (575) (1,218) - (1,218)
Profit/(loss) before finance costs and tax (1,085) 18,659 17,574 (1,217) (47,061) (48,278) (2,114) (19,545) (21,659)
Interest payable (560) - (560) (257) - (257) (663) - (663)
Profit/(loss) on ordinary activities before tax (1,645) 18,659 17,014 (1,474) (47,061) (48,535) (2,777) (19,545) (22,322)
Taxation (54) - (54) (97) - (97) (151) - (151)
Profit/(loss) for the year attributable to Shareholders (1,699) 18,659 16,960 (1,571) (47,061) (48,632) (2,928) (19,545) (22,473)
Basic and diluted earnings/(loss) per Ordinary share 3 (4.17)p 45.74p 41.57p (3.81)p (114.14)p (117.95)p (7.13)p (47.59)p (54.72)p
All revenue and capital items in the above statement derive from continuing
operations. The total column of this statement represents the Company's
Statement of Comprehensive Income, prepared in accordance with IFRSs.
The Company does not have any other comprehensive income and hence the net
profit for the year, as disclosed above, is the same as the Company's total
comprehensive income.
The revenue and capital columns are supplementary and are prepared under
guidance published by the AIC.
The notes on pages 22 to 25 form part of these Financial Statements.
STATEMENT OF CHANGES IN EQUITY
For the six months ended Called up share Share premium account Capital redemption reserve Capital reserves Revenue reserve Total
capital
28 February 2023 (Unaudited) £'000 £'000 £'000 £'000 £'000 £'000
Balance at 1 September 2022 10,346 29,873 31,482 259,849 (46,661) 284,889
Total Comprehensive Income:
Profit/(loss) for the period - - - 18,659 (1,699) 16,960
Transactions with owners, recorded
directly to equity:
Dividends paid in the period - - - (5,707) - (5,707)
Ordinary shares bought back into treasury - - - (646) - (646)
Balance at 28 February 2023 10,346 29,873 31,482 272,155 (48,360) 295,496
For the six months ended Called up Share Capital redemption reserve Capital Revenue Total
share
premium
reserves
reserve
capital
account
28 February 2022 (Unaudited) £'000 £'000 £'000 £'000 £'000 £'000
Balance at 1 September 2021 10,346 29,873 31,482 295,807 (43,733) 323,775
Total Comprehensive Income:
Loss for the period - - - (47,061) (1,571) (48,632)
Transactions with owners, recorded
directly to equity:
Dividends paid in the period - - - (6,464) - (6,464)
Ordinary shares bought back into treasury - - - (1,639) - (1,639)
Balance at 28 February 2022 10,346 29,873 31,482 240,643 (45,304) 267,040
For the year ended Called up Share Capital redemption reserve Capital Revenue Total
share
premium
reserves
reserve
capital
account
31 August 2022 (Audited) £'000 £'000 £'000 £'000 £'000 £'000
Balance at 1 September 2021 10,346 29,873 31,482 295,807 (43,733) 323,775
Total Comprehensive Income:
Loss for the year - - - (19,545) (2,928) (22,473)
Transactions with owners, recorded
directly to equity:
Dividends paid in the year - - - (12,879) - (12,879)
Ordinary shares bought back into treasury - - - (3,534) - (3,534)
Balance at 31 August 2022 10,346 29,873 31,482 259,849 (46,661) 284,889
The notes on pages 22 to 25 form part of these Financial Statements.
BALANCE SHEET AS AT 28 FEBRUARY 2023
(Unaudited) (Unaudited) (Audited)
At 28 February 2023 At 28 February 2022 At 31 August 2022
Notes £'000 £'000 £'000
Non-current assets
Investments held at fair value through profit or loss 321,668 312,388 313,429
321,668 312,388 313,429
Current assets
Receivables 9,525 188 13,487
Cash and cash equivalents - - -
9,525 188 13,487
Total assets 331,193 312,576 326,916
Current liabilities
Borrowings (24,193) (45,140) (39,976)
Payables (11,504) (396) (2,051)
(35,697) (45,536) (42,027)
Net assets 295,496 267,040 284,889
Equity attributable to equity holders
Called up share capital 10,346 10,346 10,346
Share premium account 29,873 29,873 29,873
Capital redemption reserve 31,482 31,482 31,482
Capital reserves 5 272,155 240,643 259,849
Revenue reserve (48,360) (45,304) (46,661)
Total equity 295,496 267,040 284,889
NAV per Ordinary share 6 724.88p 648.82p 697.18p
The notes on pages 22 to 25 form part of these Financial Statements.
CASH FLOW STATEMENT
(Unaudited) (Unaudited) (Audited)
For the six months ended For the six months ended For the year ended
28 February 2023 28 February 2022 31 August 2022
£'000 £'000 £'000
Cash flows from operating activities
Profit/(loss) on ordinary activities before tax 17,014 (48,535) (22,322)
Adjustments for:
Decrease in investments 5,378 32,948 19,009
(Gains)/losses on foreign exchange (564) - 4,375
(Increase)/decrease in receivables (99) 754 (33)
(Decrease)/increase in payables (112) (1,795) 261
Taxation (45) (97) (166)
Net cash flows generated from/(used in) operating activities 21,572 (16,725) 1,124
Cash flows from financing activities
Buyback of Ordinary shares into treasury (646) (1,639) (3,534)
Dividends paid (5,707) (6,464) (12,879)
Net cash used in financing activities (6,353) (8,103) (16,413)
Effect of foreign exchange rates 564 - (4,375)
Net generated from/(used in) in cash and cash equivalents 15,783 (24,828) (19,664)
Cash and cash equivalents at 1 March (39,976) (20,312) (20,312)
Cash and cash equivalents at 28 February (24,193) (45,140) (39,976)
The notes on pages 22 to 25 form part of these Financial Statements.
NOTES TO THE FINANCIAL STATEMENTS
1. ACCOUNTING POLICIES
The Financial Statements have been prepared on a going concern basis, in
accordance with International Accounting Standard 34 Interim Financial
Reporting and the accounting policies set out in the Annual Report of the
Company for the year ended 31 August 2022. Where presentational guidance set
out in the Statement of Recommended Practice (the SORP) for investment trusts
issued by the Association of Investment Companies in October 2019 is
inconsistent with the requirements of IFRS, the Financial Statements have been
prepared on a basis compliant with the recommendations of the SORP.
The interim information for each of the six month periods ended 28 February
2023 and 28 February 2022 comprises non-statutory accounts within the meaning
of Sections 434 - 436 of the Companies Act 2006 (the Act). The financial
information for the year ended 31 August 2022 has been extracted from
published accounts that have been delivered to the Registrar of Companies and
on which the report of the auditors was unqualified, did not draw attention to
any matters by way of emphasis and did not contain a statement under section
498(2) or (3) of the Act.
The Company has reviewed the guidance issued by the Financial Reporting
Council (FRC) in order to determine whether the going concern basis should be
used in preparing the Financial Statements for the six months ended 28
February 2023. The Directors have reviewed the likely operational costs and
cashflows for the Company for the 12 months from the date of this Half Yearly
Report and are of the opinion that the Company has adequate resources to
continue in operational existence for the foreseeable future. The Directors
believe that it is appropriate to adopt the going concern basis in the
preparation of the Financial Statements as there are no material uncertainties
related to events or conditions that may cast significant doubt about the
Company's ability to continue as a going concern.
The Company's principal and emerging risks remained unchanged to those
described in the Annual Report for the year ended 31 August 2022. These
include strategic/ performance risk, political risk, investment related risks,
operational risks and tax, legal and regulatory risks. These risks, and the
way in which they are managed, are described in more detail under the heading
Principal and emerging risks within the Strategic Report in the Company's
Annual Report for the year ended 31 August 2022.
2. INCOME
(Unaudited) (Unaudited) (Audited)
For the six months ended
For the six months ended
For the year ended
28 February 2023 28 February 2022 31 August 2022
£'000 £'000 £'000
Income from investments held at fair value through profit or loss:
Unfranked dividends 360 647 1,113
Franked dividends 80 - -
Other income:
Bank interest 7 - -
447 647 1,113
3. NET (LOSSES)/EARNINGS PER ORDINARY SHARE
(Unaudited) (Unaudited) (Audited)
For the six months ended
For the six months ended
For the year ended
28 February 2023 28 February 2022 31 August 2022
Net revenue loss (£'000) (1,699) (1,571) (2,928)
Net capital profit/(loss) (£'000) 18,659 (47,061) (19,545)
16,960 (48,632) (22,473)
Weighted average number of Ordinary shares in issue* 40,794,704 41,231,966 41,072,164
Pence Pence Pence
Revenue loss per Ordinary share (4.17)p (3.81)p (7.13)p
Capital profit/(loss) per Ordinary share 45.74p (114.14)p (47.59)p
Total earnings/(losses) per Ordinary share 41.57p (117.95)p (54.72)p
*Excludes those held in treasury (28 February 2023: 618,988; 28 February 2022:
225,970; 31 August 2022: 520,808).
4. INVESTMENTS HELD AT FAIR VALUE THROUGH PROFIT OR LOSS
The Company's portfolio of investments, comprising investments in companies
and any derivatives, are carried in the balance sheet at fair value. Other
financial instruments held by the Company comprise amounts due to or from
brokers, dividends and interest receivable, accruals, cash and drawings on the
credit facility. For these instruments, the balance sheet amount is a
reasonable approximation of fair value. The recognition and measurement
policies for financial instruments measured at fair value have not changed
from those set out in the statutory accounts of the Company for the year ended
31 August 2022.
The investments in the Company's portfolio are categorised into a hierarchy
comprising the following three levels:
Level 1 - valued using quoted prices in active markets.
Level 2 - valued by reference to valuation techniques using observable inputs
other than quoted market prices included within Level 1.
Level 3 - valued by reference to valuation techniques using inputs that are
not based on observable market data.
Categorisation within the hierarchy has been determined on the basis of the
lowest level input that is significant to the fair value measurement of the
relevant asset.
At 28 February 2023, the Company's investment portfolio was categorised as
follows:
(Unaudited) (Unaudited) (Audited)
At 28 February 2023 At 28 February 2022 At 31 August 2022
£'000 £'000 £'000
Level 1 286,934 284,107 285,471
Level 2 - - -
Level 3 34,734 28,281 27,958
Total 321,668 312,388 313,429
There have been no transfers between Level 1, 2 or 3 during the period (period
ended 28 February 2022 and year ended 31 August 2022: nil).
5. CAPITAL RESERVES
The capital reserve account comprises both realised gains on investments sold
and unrealised gains and losses on investments held, which are analysed as
follows:
(Unaudited) (Unaudited) (Audited)
At 28 February 2023 At 28 February 2022 At 31 August 2022
£'000 £'000 £'000
Capital reserve - on investments sold 273,192 273,449 265,122
Capital reserve - on investments held (1,037) (32,806) (5,273)
272,155 240,643 259,849
6. NET ASSET VALUE PER ORDINARY SHARE
(Unaudited) (Unaudited) (Audited)
At 28 February 2023 At 28 February 2022 At 31 August 2022
Net assets attributable to Ordinary Shareholders (£'000) 295,496 267,040 284,889
Ordinary shares in issue at end of period* 40,764,829 41,157,847 40,863,009
NAV per Ordinary share (pence) 724.88 648.82 697.18
*Excludes those held in treasury (28 February 2023: 618,988; 28 February 2022:
225,970; 31 August 2022: 520,808).
7. RELATED PARTY TRANSACTIONS
There have been no related party transactions that have materially affected
the financial position or the performance of the Company during the six month
period to 28 February 2023.
a) Transactions with the Investment Manager
Details of the management fee arrangement are given in the Directors' Report
on page 35 of the Annual Report for the year ended 31 August 2022. Following
the investment into the SV Fund VI in October 2016 and SV BCOF in December
2021, a portion of the management fee has been paid via fees due on these
investments, with the remaining fees charged directly to the Company. The
amounts paid can be seen in the table below and continue to total 0.9% of NAV.
(Unaudited) (Unaudited) (Audited)
At 28 February 2023 At 28 February 2022 At 31 August 2022
£'000 £'000 £'000
Fees paid to the Investment Manager:
Management fee paid through unquoted funds 427,556 92,353 623,361
Management fee paid by the Company directly to the Fund Manager 872,740 1,288,775 2,009,347
Total 1,300,296 1,381,128 2,632,708
A performance fee of £199,000 has been accrued as at 28 February 2023 (28
February 2022: £nil; 31 August 2022: £471,000).
b) Transactions with Key Management Personnel
The Directors of the Company are key management personnel. The total
remuneration payable to Directors in respect of the six months ended 28
February 2023 was £84,000 (28 February 2022: £80,000), of which £nil (28
February 2022: £nil) was outstanding at the period end.
8. EVENTS AFTER THE REPORTING PERIOD
After the period end and up to 28 April 2023, 176,738 Ordinary shares were
brought back to be held in treasury. Following these buybacks, the total
number of shares in issue was 41,383,817 of which 795,726 were held in
treasury.
The Directors have evaluated the period since the interim date and have not
noted any other significant events after the end of the reporting period to
the date of this Report requiring disclosure.
For further information, please contact:
Company Secretary and Registered Office
Link Company Matters Limited
6th Floor, 65 Gresham Street, London, England, EC2V 7NQ
Telephone: +44 (0)333 300 1950
Email: CompanyMatters@linkgroup.co.uk
LEI: 213800N1QUJ744P76D11
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR UPUQCAUPWGMP
Recent news on International Biotechnology Trust
See all newsRCS - Intnl. Biotechnology - Portfolio company Silence acquired by Merck KGaA
RCS - Intnl. Biotechnology - Investor Presentation via Investor Meet Company
Intnl. Biotechnology - Compliance with Market Abuse Regulation
RCS - Intnl. Biotechnology - QuotedData's In The HotSeat
Intnl. Biotechnology - Director/PDMR Shareholding